Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20509792 | 1.00 | KMT2A (0.48) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL20509670 | 0.90 | NPSR1 (0.50) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL20509859 | 0.90 | NPSR1 (0.50) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL29354583 | 0.90 | NPSR1 (0.50) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL29355343 | 0.90 | NPSR1 (0.50) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL29354778 | 0.90 | KMT2A (0.49) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL20509807 | 0.90 | KMT2A (0.49) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| SCHEMBL26705675 | 0.90 | KMT2A (0.46) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| Hydrochloric Acid SCHEMBL30644716 | 0.89 | NPSR1 (0.49) | KMT2AMEN1ALDH1A1FADS1NPSR1 | |
| Hydrochloric Acid SCHEMBL20509675 | 0.89 | NPSR1 (0.49) | KMT2AMEN1ALDH1A1FADS1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | claimed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| EP-4240369-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| CN-116472063-A | Targeted conjugates comprising modified siRNAs | 阿布特斯生物制药公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2022098990-A1 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-05-12 | — | — | WO | disclosed |
| EP-3941921-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | Arbutus Biopharma Corporation (CA) | 2022-01-26 | — | — | EP | disclosed |
| EP-3601216-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172852-A1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-27 | — | — | WO | disclosed |